Case-Control Study of Individuals With Small Fiber Neuropathy After COVID-19.
McAlpine, Lindsay, Zubair, Adeel S, Joseph, Phillip et al. · Neurology(R) neuroimmunology & neuroinflammation · 2024 · DOI
Quick Summary
This study looked at 16 patients who developed nerve damage in their small nerves after COVID-19. The researchers found that 92% of these patients also had symptoms of ME/CFS, including post-exertional malaise (feeling much worse after activity). When 9 patients were treated with IVIG (an immune therapy), all of them improved significantly, while only 3 out of 7 untreated patients improved.
Why It Matters
This study provides objective evidence linking COVID-19 to measurable nerve damage (SFN) in patients with ME/CFS-like symptoms, suggesting a potential biological mechanism for post-COVID ME/CFS. The finding that IVIG may effectively treat these symptoms offers hope for a treatable subset of long COVID patients. Understanding these connections helps validate ME/CFS as a real physiological condition and identifies potential therapeutic approaches.
Observed Findings
92% of patients with post-COVID SFN reported postexertional malaise characteristic of ME/CFS
100% (9/9) of IVIG-treated patients showed significant clinical improvement in neuropathic symptoms
43% (3/7) of untreated patients showed significant clinical improvement
7 patients with SFN who underwent iCPET demonstrated neurovascular dysregulation and dysautonomia
Median patient age was 47 years with 75% female predominance
Inferred Conclusions
Small fiber neuropathy is a treatable objective finding in post-COVID patients with ME/CFS-like symptoms
IVIG appears to be an effective treatment for post-infectious SFN associated with COVID-19
SFN in post-COVID ME/CFS may be linked to underlying dysautonomia and neurovascular dysregulation
Larger randomized controlled trials are needed to confirm IVIG's clinical utility in this population
Remaining Questions
What is the long-term durability of IVIG treatment response, and do patients require repeated infusions?
How common is SFN among the broader long COVID and ME/CFS population, and what percentage have treatable SFN?
What This Study Does Not Prove
This study does not prove that all ME/CFS cases result from small fiber neuropathy, nor does it establish that IVIG is effective for ME/CFS broadly—only for the specific subgroup with biopsy-confirmed SFN. The small sample size and retrospective design mean results may not apply to larger populations, and selection bias may have influenced which patients received treatment. Correlation between SFN and dysautonomia does not prove causation.